is today turning into solid gains as Novo Nordisk stock rises 2.5% through 11 a.m. ET. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday that Novo Nordisk ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

However, making it will require Novo Nordisk to ramp up semaglutide production even further. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday that Novo ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as ...

Novo Nordisk A/S (NVO) is a high-quality biopharma company that has been a growth play well before its recent obesity drug hit. Shares were hyped a while ago, but have now declined so much that ...